Drug Profile
Research programme: Dicer substrate siRNA oncology therapeutics - Dicerna/Ipsen
Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator Dicerna Pharmaceuticals; Ipsen
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Endocrine disorders
Most Recent Events
- 28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk
- 10 Apr 2014 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 10 Apr 2014 Discontinued - Preclinical for Endocrine disorders in USA (Parenteral)